

1-2-2008

Targeting neutrophil elastase in cystic fibrosis.

Emer Kelly

Royal College of Surgeons in Ireland

Catherine M. Greene

Royal College of Surgeons in Ireland, cmgreene@rcsi.ie

Noel G. McElvaney

Royal College of Surgeons in Ireland

Citation

Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. *Expert Opinion on Therapeutic Targets*. 2008;12(2):145-57.

This Article is brought to you for free and open access by the Department of Medicine at e-publications@RCSI. It has been accepted for inclusion in Medicine Articles by an authorized administrator of e-publications@RCSI. For more information, please contact epubs@rcsi.ie.

— Use Licence —



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Targeting neutrophil elastase in cystic fibrosis

E Kelly, CM Greene, NG McElvaney

Department of Respiratory Research, Beaumont Hospital,
Dublin, Ireland

Emer Kelly¹, MRCPI, Medical Lecturer and Respiratory Research Fellow
RCSI

Catherine M Greene¹, Senior Lecturer, RCSI

Noel G McElvaney¹, FRCPI, Professor of Medicine RCSI

¹Division of Respiratory Research, Department of Medicine, RCSI Education
and Research Centre, Royal College of Surgeons in Ireland, Beaumont
Hospital, Dublin, Ireland

Corresponding Author

Dr Emer Kelly

Department of Respiratory Research, RCSI Smurfit Building, Beaumont
Hospital, Beaumont, Dublin 9.

Email : emerkelly@rcsi.ie

Telephone: 00353868294720

Fax: 00353 18093808

Abstract

Background: Cystic fibrosis (CF) is a lethal hereditary disease characterised by neutrophil-dominated lung inflammation. These abundant neutrophils produce neutrophil elastase (NE), a destructive serine protease that has direct actions on extracellular matrix proteins and has a role in the host response to inflammation and infection.

Objective: In this review we examine the prospect of developing novel therapies for CF by targeting NE. We explore the functions of NE and of naturally occurring and synthetic NE inhibitors.

Conclusions: Targeting NE in CF offers therapeutic potential but optimal inhibitors that can be delivered safely and effectively to the lung are still under development.

Keywords

α 1-antitrypsin, cystic fibrosis, elafin, neutrophil elastase, secretory leukoprotease inhibitor

Introduction

Cystic fibrosis (CF) is a lethal hereditary disorder found mainly in Europe and North America. It is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a 27-exon, 250 kilobase segment of chromosome 7 [1-3]. This is a relatively common disorder with 1 in 20 Caucasians being heterozygotic carriers of a mutated CFTR gene and an incidence of CF of 1 in 3000 live births. Hispanics, Blacks, and Asians are also affected, but in smaller numbers [4]. CF affects the liver, pancreas and intestinal tract but the major causes of morbidity and mortality are the lung disease [5]. This generally begins in childhood with the production of thick mucus, chronic airway infections, and inflammation beginning in the early years and leading to progressive decrement in lung function and death from respiratory failure [5, 6]. Other lung complications of CF include haemoptysis, pneumothorax, pulmonary hypertension, and cor pulmonale [5, 6].

Mutations in the CFTR gene cause CFTR protein abnormalities. The mechanism by which this abnormal protein leads to the respiratory abnormalities associated with CF is not fully understood but one of the most striking features of the lung disease associated with CF is the sustained, intense neutrophil-dominated inflammation present from very early in life [7-9]. In the normal lung neutrophils account for approximately 1% of the inflammatory cell population in epithelial lining fluid (ELF) but in the CF lung neutrophils represent 70% of the ELF inflammatory cells [7-9]. These

neutrophils are ineffective in the clearance of bacteria, and play a significant role in the pathogenesis of the lung derangement associated with CF. The lung derangement is mediated in large part by neutrophil proteases and oxidants that overwhelm the normal anti-protease defence of the respiratory epithelial surface [7-11]. Neutrophil elastase (NE) is the major protease released by neutrophils in the CF lung and although it is not the only culprit causing the lung damage associated with CF, it clearly plays a major role in the process. NE has a number of different effects in the lung. It directly injures epithelial cells and interferes with the defence mechanisms of the lung by reducing ciliary beat frequency [12], it deranges mucus glycoprotein secretion [13], cleaves complement components [14, 15], and immunoglobulins [16], and interferes with the ability of neutrophils to kill *Pseudomonas* [9, 14]. More recently work from this laboratory has shown that NE plays a major role in the inactivation of elafin, a major lung anti-protease and anti-inflammatory [17]. Furthermore NE upregulates a host of pro-inflammatory cytokines in lung epithelium acting through toll-like receptors [18, 19] and the epidermal growth factor receptor [20-22]. In addition to all of this, it now seems likely that NE plays a pivotal role in the upregulation of other proteases including metalloproteases and cysteinyl cathepsins [23].

Given this background NE represents a real target for novel therapies in the treatment of CF.

Neutrophil Elastase

NE is a serine protease, a group that also includes cathepsin G and proteinase 3. NE is packaged in primary granules within neutrophils [24] (**figure 1**). It is coded for by a 4-kb (5 exon, 4 intron) gene on chromosome 19 at p13.3 [25] and the sequences for the mature NE protein are included in exons II-V. The exon structure predicts a primary translation product of 267 amino acid residues including a 29-residue N-terminal precursor containing (a) a 27-residue “pre” signal peptide followed by a “pro_n” di-peptide and (b) a 20-residue C-terminal peptide. Following synthesis, the inactive precursor molecular form is trimmed, glycosylated with complex carbohydrates, transported to the Golgi, and ultimately carried to the azurophilic granules. The cleavage of the short N-terminal propeptide is typical for the granule-associated serine proteases of cells of the hemopoietic lineage where a cysteine proteinase, dipeptidylpeptidase I (also known as cathepsin C), functions as the principal posttranslational processing enzyme [26, 27]. In common with other serine proteases, NE is stored in a fully processed and activated form [28-30]. NE is a very basic protein; because of its high content of arginine residues, it has an isoelectric point of 9.4.

The mechanism by which NE cleaves a target protein is shown in **figure 2**. The NE molecule is globular and is comprised of two complex carbohydrate side chains attached to Asn⁹⁵ and Asn¹⁴⁴. The catalytic site of the NE molecule is an indentation of the molecule and is composed of the molecule and the triad His⁴¹-Asp⁹⁹-Ser¹⁷³, in which the γ -oxygen of serine becomes a

powerful nucleophile able to attack a suitably located carbonyl group on the target substrate. The bond to be cleaved must fit into the active site pocket of the NE held there by charge interactions and mediated by the residues forming the pocket. The peptide bond under attack is between two amino acid residues recognized by their side chains. An acyl-enzyme intermediate molecule is formed between serine and the carbonyl group on the target protein. To complete the process, the acyl-enzyme complex is hydrolysed with subsequent regeneration of active NE and cleavage of the protein.

Neutrophil elastase functions (figure 3)

NE is a powerful degrading enzyme and much research has been carried out to investigate this. Millimolar concentrations of NE, when released from single azurophilic granules of activated neutrophils, lead to evanescent quantum bursts of proteolytic activity before catalysis is halted by pericellular inhibitors. The manner in which NE degrades extracellular matrix despite the presence of functioning anti-protease molecules is still not fully understood. One theory holds that neutrophils can release oxidants which locally inactivate antiproteases thereby permitting NE to act on the local tissues. Work from Campbell's group looked at the function of NE as regards quantum proteolysis [31]. Calculations from first principles indicate that approximately 67,000 molecules of NE are stored in each azurophilic granule at a mean concentration of 5.33 mM, which exceeds pericellular inhibitor concentrations *in vivo* by nearly three orders of magnitude. Diffusion analysis predicts obligate catalytic activity (excess of local enzyme over inhibitor concentration)

that extends to 1.33 microns from the site of granule extrusion (7.8-fold larger than the mean radius of the granule), with a duration of 12.4 ms, when the pericellular concentration of α 1AT equals that of normal plasma. In contrast, when polymorphonuclear cells are bathed in α 1AT concentrations found in plasma from individuals with α 1AT deficiency, the radius and duration of obligate catalytic activity are increased 2.5-fold and 6.2-fold, respectively. These simulations agree remarkably well with direct observations and provide a novel, nonoxidative mechanism by which quantum bursts of extracellular proteolytic activity occur despite proteinase inhibitors in the bathing medium. Titration of local enzyme-inhibitor concentration is the dominant determinant of the size and duration of such events. Work with α 1AT deficiency serum samples showed that quantum proteolytic events are abnormally large and prolonged in α 1AT deficiency, leading directly to an increased risk of tissue injury in the immediate vicinity of activated neutrophils [32]. This may give an insight into the destructive activity of NE in patients with CF, where the problem of protease antiprotease balance is not one of inhibitor deficiency but rather enzyme excess.

The term neutrophil elastase is partly a misnomer as not only does NE degrade elastin but also degrades almost all extracellular matrix and key plasma proteins. NE has broad substrate specificity and is capable of degrading a wide range of extracellular matrix proteins including elastin, collagen (types I-IV), fibronectin, laminin, and proteoglycans [33-37]. Other extracellular matrix proteins degraded include platelet IIb/IIIa receptor, complement receptor, thrombomodulin, lung surfactant, and cadherins [38-

42]. In addition, NE can cleave coagulation factors (fibrinogen and factors V, VII, XII, and XIII), plasminogen, IgG, IgA, and IgM, complement factors C3 and C5, complement receptors, and gp120, the coat protein of the human immunodeficiency virus [43-45]. It may also cleave other proteases found within neutrophil granules [46] and also other protease inhibitors [47, 48] leading to their activation or their loss of function. **(Table: 1)**

NE has also been shown to upregulate pro-inflammatory cytokines. For example, NE upregulates IL8 expression and secretion from bronchial epithelial cells by signalling through toll-like receptor 4 (TLR4) [49, 18]. NE-induced upregulation of IL8 expression in human bronchial epithelial cells depends on the proteolytic activity of NE, as inhibition with the serine-protease inhibitor phenylmethylsulphonyl fluoride (PMSF) abolishes this specific activation. Similarly, Tsujimoto et al. showed that pre-treatment with an inhibitor of NE decreased lipopolysaccharide (LPS)-induced CXCL2 production by the human macrophage cell line RAW 264.7 in a dose-dependent manner [50]. NE also upregulates leukotriene B4 (LTB4) secretion from macrophages [51].

NE contributes to chronic inflammatory airway diseases by inducing mucin production in airway epithelial cells [20]. The exact mechanism by which NE mediates this effect is unclear but has been shown to involve activation of protein kinase C (PKC) and production of reactive oxygen species (ROS). ROS in turn activate TNF- α (tumour necrosis factor- α)-converting enzyme (TACE), leading to TACE-dependent release of soluble transforming growth

factor- α (TGF α) and TGF α stimulation of epidermal-growth-factor receptor (EGFR), which induces the production of mucin [21]. However other metalloproteases may also be involved in these processes including meprin α [22].

NE and other serine proteases have also been shown to have an effect at the cell surface. NE can cleave cell-surface adhesion molecules, such as intercellular adhesion molecule 1 (ICAM1), vascular cell-adhesion molecule 1 (VCAM1) and epithelial (E)-cadherin [52-54]. As cell migration involves a series of attachment and detachment events, the shedding of adhesion molecules from the cell surface by proteases might provide a mechanism to regulate and terminate cell-cell or cell-extracellular matrix interactions. It is postulated that serine proteases are involved in activation of the pro-form of tumour necrosis factor and interleukin-1 β [55, 56] but interestingly NE and cathepsin G both degrade mature TNF [57] and all three serine proteases can inactivate IL-6 [58].

Although much research has centred on the destructive nature of NE in degrading a multitude of proteins, recent evidence has emphasised the role of NE in the host immune response to infection. For example, while neutrophils may migrate normally to sites of infection in the absence of NE, NE is required for maximal intracellular killing of Gram-negative bacteria by neutrophils [59]. In addition to the intracellular activities of the neutrophil serine proteases, it has been shown that serine proteases released from neutrophils form neutrophil extracellular traps (NETs) with chromatin and that NETs bind

Gram-positive and Gram-negative bacteria [60]. These NETs allow neutrophils to deliver high concentrations of serine proteases that degrade virulence factors and kill bacteria extracellularly. A proportion of NE remains bound to the cell surface of neutrophils when azurophilic granules fuse with the plasma membrane during exocytosis. The concentrated expression of the neutrophil serine proteases on the outer surface of the plasma membrane [61, 62] allows neutrophils to modulate the inflammatory response. In support of this idea, inhibition of neutrophil serine proteases has been shown to reduce neutrophil infiltration and neutrophil-mediated injury in various modes of inflammation, including ischaemia and reperfusion injury, endotoxin-induced acute lung injury and collagen-induced arthritis [63-65].

These data show that there is a fine balance between the physiologic and deleterious effects of NE. When this balance is disturbed, as in the case of α 1AT deficiency where there is too little NE-inhibition or in CF where there is dysregulated NE release, lung damage results. While it is generally accepted that large quantities of active extracellular NE in the lung is potentially deleterious and should be inhibited to prevent further lung damage, intracellular and locally expressed NE may be important for host defence and should not be inhibited. This has important implications for the type of inhibitors which should be used.

Anti-NE Defences of the lung

In normal lungs the anti-NE defences include, α 1AT, secretory leukoprotease inhibitor (SLPI) and elafin. Individuals with CF have normal serum and ELF levels of all three [7, 8]. α 1AT is produced in the liver and from there circulates to the lung where it provides the major anti-NE protection to the lower respiratory tract [66]. The importance of α 1AT and NE in lung protection and destruction respectively is illustrated by α 1AT deficiency, a hereditary disorder associated with polymerisation of the mutant α 1AT in the liver, decreased secretion of α 1AT into the circulation and a markedly diminished anti-NE protective defence in the lung [67]. This condition is associated with premature aggressive emphysema, a condition which is aggravated greatly by the effects of cigarette smoke in oxidising and further inactivating α 1AT leading to an unopposed action of NE [68].

The roles of SLPI and elafin in protecting the lung from NE are less well defined. Both of these molecules are produced locally by epithelial cells and it has been suggested that SLPI may function as an anti-NE molecule mostly in the upper airways. More recently research has focussed on the anti-inflammatory effects of these molecules and by extension on the deleterious effects of NE in inhibiting these activities. SLPI and elafin have been shown to inhibit nuclear factor-kappa B (NF κ B) activation, and IL-8 and monocyte chemoattractant protein-1 (MCP-1) production by epithelial cells and monocytes. However, whereas elafin is inactivated by NE in CF ELF [17], SLPI is relatively immune to the direct proteolytic effects of NE but is readily proteolysed by cysteinyl cathepsins [69] and metalloproteases both of which

are upregulated by NE [23]. CysteinyI proteases also cleave and inactivate defensins [70] and lactoferrin, two locally produced anti-microbials with direct relevance to CF as defensins are key mediators of *Pseudomonas* killing and lactoferrin has a major role in inhibiting biofilm formation [71].

Individuals with CF have normal to high serum and ELF levels of all three of the major anti-NE compounds [7, 8]. However, α 1AT, elafin and SLPI in CF ELF are completely inactive, being complexed with or cleaved by NE and other proteases or rendered impotent by oxidants produced by inflammatory cells [7, 8]. The presence of large amount of neutrophils on the respiratory epithelial surface, brought there by abundant neutrophil chemoattractants (including IL8, Leukotriene B4, C5A) and α 1AT-NE complexes results in large quantities of unopposed NE on the respiratory epithelial surface of individuals with CF. The levels of NE in CF ELF vary markedly, but can be as high as 100 μ M. These levels correlate inversely with pulmonary function in individuals with CF. This illustrates one of the enduring difficulties in dealing with the neutrophil dominated inflammation in CF, namely the recurring cycle of NE induced inflammation. NE upregulates IL8 from epithelial cells and LTB4 from macrophages creating a gradient of neutrophil chemoattraction bringing more neutrophils onto the epithelial surface where they are readily activated to produce more NE by cytokines such as IL8 and TNF. Adding to this complexity the neutrophil in individuals with CF is also intrinsically abnormal and secretes more NE than non-CF neutrophils in response to IL8, TNF and LPS all of which are found in abundance in the CF lung [72].

Targeting neutrophil elastase in cystic fibrosis

(figure 4)

Strategies to prevent NE-mediated lung derangement in CF are based on the theory of increasing the level of antiproteases available to inhibit NE or lowering the burden of NE in the lung. In CF, the levels of NE in ELF vary dramatically from individual to individual, and even in the same individual over time, so that it is difficult to determine the level of augmentation required.

Approaches to augment the anti-NE defenses of the lung in CF include (a) augmentation with plasma purified α 1AT, (b) augmentation using recombinant antiproteases or other naturally occurring antiproteases, (c) use of chemical antiproteases, and (d) gene therapy. The inhibition of NE in CF, should not only directly protect the lung but also lower the neutrophil burden, and enhance host defence by protecting complement, complement receptors, and locally produced antimicrobials and antiinflammatories such as SLPI, elafin, defensins and lactoferrin.

Augmentation with purified plasma α 1AT

Much of the work on intravenous administration of purified α 1AT has been carried out in the context of α 1AT deficiency. The seminal paper by Wewers et al [73] showed that once weekly intravenous administrations of plasma purified α 1AT led to levels of serum α 1AT above a putative protective threshold of 11 μ M throughout the duration of therapy. This serum data was complemented by data showing that ELF levels of α 1AT and anti-NE capacity were also raised by this intravenous administration to the normal α 1AT ELF levels. As a next step from this it was deemed logical that the enormous NE

burden on the epithelial surface in CF could be inhibited by intravenous augmentation with α 1AT [8]. Purified plasma α 1AT was administered at dosages ranging from 60 to 120 mg/kg once weekly. However, only dosages in the 120-mg/kg range were able to elevate α 1AT levels sufficiently to inhibit the NE burden in these individuals. Unfortunately, the inhibition was brief, with reappearance of active NE on the respiratory epithelial surface within 1 week after administration, suggesting that this approach, although effective in the short term was not feasible as it would require frequent intravenous administration of large doses of α 1AT to have the desired effect. Recombinant forms of α 1AT have not been effective when administered intravenously as those raised in yeast are non-glycosylated with a resultant very short plasma half life while those produced from transgenic animals had different glycosylation to plasma purified α 1AT also leading to alterations in half life. [74-76]. Animal studies evaluating intravenous infusion of SLPI showed an unacceptably high level of proteinuria [77]. Slowing the infusion decreased the levels of protein in urine but this approach has not been pursued. Because of these results and because CF is mainly a bronchial disease it was decided that aerosolization of α 1AT to the lungs of individuals with CF would offer benefits.

Aerosol Augmentation with α 1AT

This was first attempted in 1991 [66]. 1.5-3mg/kg of purified plasma α 1AT was administered twice daily to individuals with CF. This resulted in inhibition of NE on the respiratory epithelial surface and re-establishment of the ELF anti-

NE capacity, but only if the levels of α 1AT in ELF exceeded $8\mu\text{M}$. However this study also highlighted another potentially useful effect of inhibiting NE in CF. After suppression of the NE burden in CF ELF with aerosolized α 1AT, the ability of CF ELF to inhibit neutrophil killing of *Pseudomonas* was abolished. This was due in part to the inhibition of NE in CF ELF preventing it from cleaving complement receptors on the neutrophils. Furthermore suppression of NE in CF is associated with decreased IL-8 in CF ELF and decreased neutrophil numbers on the epithelial surface [8]. These findings have been replicated by others. Berger et al showed that aerosolised plasma purified α 1AT inhibited NE in ELF and that this inhibition was related to the doses of α 1AT delivered [78]. They did not show a significant effect on IL-8 or neutrophil count. Interestingly there was no correlation between sputum and ELF NE levels. A recent study from Griese et al, examined the effect of 4 weeks of plasma purified α 1AT inhalation on lung function, protease-antiprotease balance and airway inflammation in CF patients [79]. They found that this therapy increased α 1AT levels and decreased the levels of NE activity, neutrophils, pro-inflammatory cytokines and the numbers of *P. aeruginosa*. However, as might be expected, given the short duration of this study, there was no effect on lung function. This study mainly evaluated sputum based parameters and speculated on the reasons for some of the differences noted between parameters measured in sputum and ELF.

Secretory Leukoprotease Inhibitor

Another candidate as an anti-NE molecule for CF is recombinant SLPI, a 12-kDa-nonglycosylated single-chain polypeptide identical to the naturally

occurring SLPI [80-83]. Advantages of SLPI as a potential therapeutic option are that it is acid stable which may allow it to retain function in the acidic pH of the metabolically active neutrophils [84, 85], its isoelectric point of 9 is close to that of NE which may allow it to track and bind to tissue sites favoured by NE [86, 87], its relative imperviousness to degradation by NE and its possible enhanced antioxidant function by increasing glutathione levels in the local milieu [88]. Despite the postulated advantages, delivery of SLPI to the lungs has proven unimpressive [89]. Aerosolization of 100 mg of recombinant SLPI twice daily to individuals with CF was associated with inhibition of NE on the respiratory epithelial surface, as well as decreases in the levels of IL-8 and neutrophil numbers in ELF [8]. However, relatively more recombinant SLPI than α 1AT is required to suppress ELF NE levels in individuals with CF. Furthermore, recombinant SLPI does not accumulate on the respiratory epithelial surface either in controls or in individuals with CF, and most of the anti-NE effects are gone within 12 hours of administration. The reasons for this are not fully elucidated but may be due to compartmentalization of SLPI to the epithelial surface, absorption of recombinant SLPI into epithelial cells and macrophages, and/or binding of recombinant SLPI to molecules in the interstitium after passing through the epithelium [89, 7]. Also more recently it has been shown that SLPI is easily degraded by cysteinyl cathepsins which are present in very high quantities in CF ELF [69]. Thus, although SLPI has several theoretical advantages to augment anti-NE in the lung, the successful use of the molecule as an effective therapy for CF presents considerable challenges.

Other naturally occurring antiproteases

Elafin is a cationic protease inhibitor of human NE, proteinase 3, and porcine pancreatic elastase. It was previously shown that elafin and its precursor trappin-2 retain the ability to inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase [90]. More recent work in U937 cells showed that elafin inhibits LPS-induced production of MCP-1 by preventing the LPS-induced activation of AP-1 and NF κ B [91]. This anti-inflammatory effect appears to be dependent upon an effect of elafin on the ubiquitin-proteasome pathway. Due to the selective expression of elafin at mucosal surfaces, as well as in alveolar macrophages, monocytes and neutrophils, the ability of elafin to inhibit LPS signalling may be important in CF and may represent another therapeutic option. Unfortunately in areas of NE excess elafin is degraded and inactivated by the NE [17].

Human monocyte/neutrophil elastase inhibitor (MNEI), a 42-kDa serine protease inhibitor (serpin) protein, is an effective inhibitor of NE, cathepsin G, and proteinase-3 [92]. Recombinant MNEI has been given daily by aerosol to rats, previously infected with *P. aeruginosa*. The treatment with MNEI significantly decreased the extent of inflammatory injury and improved clearance of bacteria from the infected rat lungs. Similar results have been obtained for aerosolized α 1AT in a rat model of CF lung inflammation [93]. This suggests another potential parameter to evaluate the efficacy of anti-protease therapy in CF.

Other naturally occurring antiproteases include eglin-c, a single-chain polypeptide purified from the medicinal leech *Hirudo medicinalis*.

Recombinant eglin-c inhibits NE and cathepsin G, as well as several other proteases, and intratracheal instillation of eglin-c has been shown to attenuate the severity of NE induced emphysema in hamsters [94-96]. However, as might be expected of a protein from a nonhuman source, eglin-c is allergenic to humans and cannot be used clinically in its present form.

NE is markedly inhibited by *cis*-unsaturated fatty acids, such as oleic acid. A family of serine protease inhibitors has been identified in the seeds of squash (*Curcubita maxima*), several of which might be potentially useful [97]. A number of NE inhibitors have been isolated from microorganisms, including elasnin, elasninal, chymostatin, leupeptin, valinal, and antipain [98]. As for eglin-c the clinical application of these substances is limited by the possibility of immune reactions.

Three naturally occurring dithiol reducing systems have been examined for their effects on elastase activity: 1) *Escherichia coli* thioredoxin (trx) system, 2) recombinant human thioredoxin (trx) system, and 3) dihydrolipoic acid (DHLA) [99]. The ability of Trx and DHLA to limit elastase activity combined with their mucolytic effects makes these compounds potential therapies for CF.

More recently work has been done on greglin, a novel locust serine protease inhibitor with a high affinity for NE [100]. This is a fast acting and tight binding

inhibitor of human NE, which also binds neutrophil cathepsin G, pancreatic elastase and chymotrypsin with lower affinity. This has been shown to inhibit NE activity in sputum supernatants from CF patients.

Low-molecular weight inhibitors of NE

A number of synthetic NE inhibitors have been developed as potential therapeutic agents for α 1AT deficiency. These include irreversible inhibitors such as the peptide chloromethyl ketones [101] and reversible inhibitors such as peptide boronic acids [102], peptide aldehydes [103], substituted tripeptide ketones [104], or β -lactams that have been modified to inhibit NE [105]. One of the problems with the low-molecular-weight reversible inhibitors is that they can release NE, allowing it to destroy tissue. Although the irreversible inhibitors such as chloromethyl ketone have been shown to function effectively *in vivo* in hamsters to reduce many of the effects of intratracheally administered NE, the toxicity of chloromethyl ketones prevents clinical use.

β -lactam-based compounds have been identified as specific potent inhibitors of NE [105]. The fact that these molecules clear rapidly from circulation suggests that they may be limited to aerosol therapy. From kinetic data, Gorrini et al concluded that the macrolide antibiotic erythromycin acts as an alternate substrate NE inhibitor and that flurythromycin acts as an inactivator [106]. L-658,758, a cephalosporin-based drug, is another antibiotic which has inhibitory effects on NE, proteinase-3 and CF sputum soluble elastase [107].

Small molecules can gain access to tissue sites inaccessible to larger molecules. This is a potential advantage and a potential disadvantage. While these inhibitors may prevent NE from attacking connective tissue in confined areas such as beneath the surface of neutrophils they may also inhibit proteases at sites where they perform a physiological function, such as intracellularly or in their role as facilitators of cell movement through tissue [108].

Initial work *in vivo* and *in vitro*, in rats, on a new, rapidly acting, potent and specific NE inhibitor, EPI-HNE-4 demonstrated an effective inhibition *in vitro* of the high levels of active NE present in a medium as complex as sputum from children with CF by almost complete block of N-formyl-methionine-leucine-phenylalanine-induced migration of purified human neutrophils across a Matrigel basement membrane [109]. Intratracheal administration of EPI-HNE-4 and intravenous administration brought about inhibition of NE and of neutrophil influx in the rat. This suggested a potential for associated aerosol and systemic administration of EPI-HNE-4 in the treatment of CF. Further work on this agent showed that it can be nebulised efficiently without decrease in its activity and that mixing the inhibitor with (99m)Tc human serum albumin tracer should allow quantification of its deposition in CF patients [110]. EPI-HNE4 is also resistant to hydrolysis by neutrophils in inflammatory lung secretions, including metalloproteases (MMPs) 7, 8 and 9, and the elastase-related protease 3 and cathepsin G [111]. While these initial results are encouraging this agent is still some distance from demonstration of clinical efficacy.

Gene therapy

Whilst various viral vectors continue to be evaluated as a method of transfer of CFTR in CF [112], the delivery of the α 1AT cDNA via different vectors to increase the antiprotease activity in CF is another possibility. Plasmid cationic liposome mediated α 1AT gene transfer to a CF bronchial epithelial cell line was first performed in 1996 [113]. This protected the cells from NE damage. To date there have been a number of animal studies evaluating the potential of transferring the α 1AT cDNA to muscle liver and lung in the hope of producing therapeutic levels of α 1AT in plasma. These studies used an adeno-associated virus vector delivery system and achieved significant levels of α 1AT over prolonged periods of time, up to months, and a subsequent phase I trial revealed no serious vector-related adverse events [114]. However to date no human trials have been forthcoming probably because of the availability of an alternative in plasma purified augmentation therapy.

Delivering an agent to the lung

A further hurdle to the targeting of NE to achieve therapeutic potential in CF is the delivery of an agent to the lung. This is a problem that has been faced in attempting to optimise delivery of antibiotics to the lung in CF [115]. There are many advantages to aerosol delivery as opposed to systemic administration; the agent is delivered directly to the site of action, there is less systemic toxicity, it can be self administered and higher concentrations are available at the site of the lung disease. Drawbacks of this approach include difficulties in determining pharmacokinetics and sampling of ELF to quantify inhibitory

effects. Nebulisation can affect drug activity and, depending on whether administration is preferable in the upper or lower airways, optimum particle size and device type must be evaluated. Factors such as biofilm, the physical and chemical composition of mucus and the degree of parenchymal destruction and bronchiectasis in CF patients can significantly alter drug distribution and bioavailability. In the case of antibiotics two classes of antagonistic sputum components have been identified. They are small molecules which physically decrease antibiotic penetration into bacteria, and large glycoprotein molecules, which bind and sequester aminoglycosides [116]. Sputum glycoproteins such as mucin and DNA in CF patients can bind polycations such as aminoglycosides. Glycoprotein content varies amongst CF patients but can bind approximately 90% of the drug. Soluble sputum components such as monovalent and divalent cations, vary little among patients [117]. Divalent ions bind approximately 5% of aminoglycoside given and DNA binds approximately another 2%.

The desired properties of an ideal aerosolised therapeutic agent in CF patients are many. Particle sizes ranging from 1 to 5 μm appear to be optimal for reproducible drug delivery to the airways [118, 119]. The agent should be sterile and nonpyrogenic as allergic reactions to impure recombinant or plasma-purified preparations may occur [120]. To aid in patient compliance it should be reasonably palatable. To allow for the varying conditions that it will encounter in the lungs of CF patients which will alter the delivered concentration it should have a wide margin of dosage safety. The ideal

aerosolised agent should be easily nebulised and should be chemically stable.

Expert Opinion

There is no doubt that the lung disease in CF is mediated, at least in part, by the effects of NE. These effects are myriad, directly acting to degrade extracellular matrices, impairing host defence, increasing mucin and cytokine production and upregulating other potentially deleterious proteases in the lung. Whereas normally NE has an important role itself in host defence, in CF the secretion of NE is dysregulated so that there is an excess of extracellular NE and the normal anti-NE protective mechanisms are ineffective. In this context it makes sense that extracellular active NE in the lung epithelial surface should be inhibited. Given the newly discovered anti-inflammatory effects of many anti-NE molecules it becomes more important than ever to try to restore the normal NE/anti-NE balance in the CF lung. At the present time most experience is with the natural inhibitors of NE such as plasma purified α 1AT but other recombinant and synthetic molecules are being studied. The major problems with plasma-purified α 1AT have been fears of blood borne infections and lack of supply. Recombinant preparations also have potential problems; some cannot be given by intravenous route and those given by aerosol need to be rigorously tested for impurities. The future is likely to see customised combinatorial therapies designed specifically for CF patients that take into account bacterial colonisation status, NE activity, and mucus, DNA and glycoprotein levels. Aerosolisation is the most promising route of administration and aerosolisation of anti-NE molecules may be combined with

other aerosolisation therapeutics. Problems posed by drug binding and sequestration, charge factors and accessibility to the airway epithelium pose major challenges and advances in delivery technologies are needed.

The effects of successful anti-NE therapy will need to be evaluated at a variety of levels. Firstly the therapies must be shown to inhibit NE and in doing so decrease other pro-inflammatory cytokines and proteases. Conceivably this could lead to decreased bacterial load which could serve as a useful surrogate measure of clinical efficacy both in short term and long term studies. The previous gold standard in all lung studies of an improvement or decreased deterioration in pulmonary function will not be achievable in short term studies and may best be reserved for the more definitive stage 3 studies along with other measures such as quantitative CT scanning.

References

1. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. *Science* (1989);245:1073-1080
2. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* (1989);245:1066-1073

3. Rommens JM, Iannuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* (1989);245:1059-1065
 4. Tsui LC, Buchwald M. Biochemical and molecular genetics of cystic fibrosis. *Adv Hum genet* (1991);20:153-266, 311-312
 5. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. *The Metabolic Basis of Inherited Disease*. New York: McGraw-Hill, (1989);2649-2680
 6. Welsh MJ, Fick RB. Cystic fibrosis. *J Clin Invest* (1987);80:1523-1526
 7. Birrer P, McElvaney NG, Rudeberg A et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. *Am J Respir Crit Care Med* (1994);150:207-213
- * Informative article setting the scene for review
8. McElvaney NG, Nakamura H, Birrer P et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. *J Clin Invest* (1992);90:1296-1301.

9. McElvaney NG, Hubbard RC, Birrer P et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. *Lancet* (1991);337:392-394

10. Suter S. The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis. *Antibiot Chemother* (1989);42:158-168

11. Rourm JH, Buhl R, McElvaney NG et al. Systemic deficiency of glutathione in cystic fibrosis. *J Appl Physiol* (1993);75(6):2419-24

12. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. *Thorax* (1984);39:663-667

13. Breuer R, Christensen TG, Niles RM et al. Human neutrophil elastase causes glycoconjugate release from the epithelial cell surface of hamster trachea in organ culture. *Am Rev Respir Dis* (1989);139:779-782

14. Berger M, Sorensen RU, Tosi MF et al. Complement receptor expression on neutrophils at an inflammatory site, the *Pseudomonas*-infected lung in Cystic Fibrosis. *J Clin Invest* (1989);84:1302-1313

15. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized *Pseudomonas* as well as CR1 on neutrophils to create a

- functionally important opsonin receptor mismatch. *J Clin Invest* (1990);86:300-308
16. Fick RB Jr, Naegel GP, Squier SU et al. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. *J Clin Invest* (1984);74:236-248
17. Guyot N, Butler MW, McNally P et al. Elafin, an elastase specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. Abstract 41, 5^{eme} Colloque Proteolyse Cellulaire – Programme March 2007
18. Devaney JM, Greene CM, Taggart CC et al. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. *FEBS Lett* (2003);544:129-132
19. Greene CM, Carroll TP, Smith SG et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. *J Immunol* 2005;174(3):1638-46
20. Fischer BM, Voynow JA. Neutrophil elastase induces MUC5AC gene expression in airway epithelium via a pathway involving reactive oxygen species. *Am J Respir Cell Mol Biol* 2002;26:447-452

21. Shao MX, Ueki IF, Nadel JA. Tumor necrosis factor α -converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. *Proc Natl Acad Sci USA* 2003;100:11618-11623
22. Bergin DA, Greene CM, Taggart CC et al. The Involvement of a Zinc Endopeptidase, Meprin, in NE-Induced Inflammation in Airway Epithelial Cells. A321 American Thoracic Society 2007 Abstract
23. Geraghty P, Rogan MP, Greene CM et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. *J Immunol* 2007;178(9):5871-8
24. Jenne DE. Structure of the azurocidin, proteinase 3, and NE genes: implications for inflammation and vasculitis. *Am J Respir Crit Care Med* 1994;150:S147-S154
25. Zimmer M, Medcalf RL, Fink TM et al. Three human elastase-like genes co-ordinately expressed in the myelomonocyte lineage are organised as a single genetic locus on 19pter. *Proc Natl Acad Sci USA* 1992;89:8215-8219
26. Salvesen G, Enghild JJ. An unusual specificity in the activation of neutrophil serine proteinase zymogens. *Biochemistry* 1990;29:5304-5308

27. McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase i. *J Biol Chem* 1993;268:2458-2467
28. Barret AJ. Leukocyte elastase. *Methods Enzymol* 1981;80 Part C: 581-588
29. Fouret P, Du Bois RM, Bernaudin JF et al. Expression of the neutrophil elastase gene during human bone marrow cell differentiation. *J Exp Med* 1989;169:833-845
30. Sinha S, Watorek W, Karr S et al. Primary structure of human neutrophil elastase. *Proc Natl Acad Sci USA* 1987;84:2228-2232
31. Liou TG, Campbell EJ. Nonisotropic enzyme--inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. *Biochemistry* 1995 Dec 12;34(49):16171-7
32. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in α_1 -antitrypsin deficiency. *J Clin Invest.* 1999; 104(3): 337–344
33. Barrett AJ. An introduction to the proteinases. In: Barrett AJ, Salvesen G, eds. *Protease inhibitors*. New York: Elsevier;1986:1-22

34. Bieth JG. Elastases: Catalytic and biological properties. In: Mecham R, eds. Regulation of matrix accumulation. New York: Academic Press;1986:217-230
35. Gadek JE, Fells GA, Wright DG, Crystal RG. Human neutrophil elastase functions as a type III collagen "collagenase." *Biochem Biophys Res Commun* 1980;95:1815-1822
36. Janoff A. Elastase in tissue injury. *Annu Rev Med* 1985;36:207-216
37. Janoff A, Scherer J. Mediators of inflammation in leukocyte lysosomes, ix: Elastinolytic activity in granules of human polymorphonuclear leukocytes. *J Exp Med* 1968;128:1137-1155
38. Abe H, Okajima K, Okabe H et al. Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. *J Lab Clin Med* 1994; 123:874-881
39. Ariel A, Yavin EJ, Hershkovic R et al. IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. *J Immunol* 1998; 161:2465-2472

40. Carden D, Xiao F, Moak C et al. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. *Am J Physiol* 1998; 275:H385-H392

41. Ginzberg HH, Cherapanov V, Dong Q et al. Neutrophil-mediated epithelial injury during transmigration: role of elastase. *Am J Physiol* 2001;281:G705-G717

42. Liao DF, Yin NX, Huang J, Ryan SF. Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. *Biochim Biophys Res Commun Acta* 1979;1302:117-128

43. Havemann K, Janoff A. Neutral proteases of human polymorphonuclear leukocytes. Baltimore, MD: Urban & Schwarzenberg;1978

44. Bieth JG. Elastases: Catalytic and biological properties. In: Mecham R, eds. Regulation of matrix accumulation. New York: Academic Press;1986:217-230

45. States DJ, Fells GA, Crystal RG. Susceptibility of the HIV envelope protein to attack by neutrophil elastase. *Clin Res* 1989;37:482A

46. Senior RM, Campbell EJ. Neutral proteinases from human inflammatory cells. A critical review of their role in extracellular matrix degradation. Clin Lab Med 1983;3:645-666
47. Havemann K, Gramse M. Physiology and pathophysiology of neutral proteinases of human granulocytes. Adv Exp Med Biol 1984;167:1-20
48. Okada Y, Watanabe S, Nakanishi I et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 1988;229:157-160
49. Walsh DE, Greene CM, Carroll TP et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001;276:35494-35499
50. Tsujimoto H, Ono S, Majima T et al. Neutrophil elastase, MIP-2 and TLR-4 expression during human and experimental sepsis. Shock 2005;23:39-44
51. Hubbard RC, Fells G, Gadek J et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88(3):891-

52. Champagne B, Tremblay P, Cantin A, St Pierre Y. Proteolytic cleavage of ICAM-1 by human neutrophil elastase. *J Immunol* 1998;161:6398-6405
53. Levesque JP, Takamatsu Y, Nilsson SK et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. *Blood* 2001;98:1289-1297
54. Ginzberg HH, Cherapanov V, Dong O et al. Neutrophil-mediated epithelial injury during transmigration: role of elastase. *Am J Physiol Gastrointest Liver Physiol* 2001;281:G705-G717
55. Black RA, Rauch CT, Kozlosky CJ et al. A Metalloproteinase disintegrin that releases tumour-necrosis factor- α from cells. *Nature* 1997;385:729-733
56. Thornberry NA, Bull HG, Calaycay JR et al. A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes. *Nature* 1992;356:768-774
57. Scuderi P, Nez PA, Duerr ML et al. Cathepsin G and leukocyte elastase inactivate human tumor necrosis factor lymphotoxin. *Cell Immunol* 1991;135:288-313

58. Bank U, Kupper B, Reinhold D et al. Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation. *FEBS Lett* 1999;461:235-240
59. Belaouaj A, McCarthy R, Baumann M et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. *Nat Med*.1998;4(5):615-8
60. Brinkmann V, Reichard U, Goosmann C et al. Neutrophil extracellular traps kill bacteria. *Science* 2004;303:1532-1535
61. Owen CA, Campbell MA, Sannes PL et al. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. *J. Cell Biol.* 1995;131:775-789
62. Campbell EJ, Campbell MA, Owen CA: Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. *J Immunol* 2000;165:3366-3374
63. Carden DL, Korthuis RJ. Protease inhibition attenuates microvascular dysfunction in postischemic skeletal muscle. *Am J Physiol* 1996;271:H1947-52

64. Kawabata K, Hagio T, Matsumoto S et al. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. *Am J Respir Crit Care Med* 2000;161:2013-2018
65. Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H. Suppressing effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. *Cell Immunol* 1995;165:26-32
66. McElvaney NG, Hubbard RC, Birrer P et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. *Lancet* 1991;337:392-394
67. Gadek JE, Crystal RG. Alpha 1-antitrypsin deficiency. In: Stanbury JB, Wyngaarden JB, Frederickson DS, et al. eds. *The metabolic basis of inherited disease*. New York: McGraw-Hill, 1983:1450-67
68. Taggart C, Cervantes-Laurean D, Kim G et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. *J Biol Chem* 2000;275(35):27258-65
69. Taggart CC, Lowe GJ, Greene CM et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. *J Biol Chem*. 2001;276(36):33345-52

70. Taggart CC, Greene CM, Smith SG et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. *J Immunol* 2003;171(2):931-7
71. Rogan MP, Taggart CC, Greene CM et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. *J Infect Dis* 2004;190(7):1245-53
72. Taggart C, Coakley RJ, Grealley P et al. Increased elastase by CF neutrophils is mediated by tumor necrosis factor alpha and interleukin-8. *Am J Physiol Lung Cell Mol Physiol* 2000;278:L33-41
73. Wewers MD, Casolaro MA, Sellers SE et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. *N Engl J Med* 1987;316:1055-1062
74. Courtney M, Jallat S, Tessier IH et al. Synthesis in *E. coli* of alpha 1-antitrypsin variants of therapeutic potential for emphysema and thrombosis. *Nature* 1985;313:149-151
75. Rosenberg S, Barr PJ, Najarian RC, Hallewell RA. Synthesis in yeast of a functional oxidation-resistant mutant of human alpha-antitrypsin. *Nature* 1984;312:77-80

76. Casolaro MA, Fells G, Wewers M et al. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol 1987;63:2015-2023

77. Birrer P, McElvaney NG, Gillissen A et al. Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense. J Appl Physiol. 1992;73:317-23

*Important article referring to potential therapeutic target

78. Berger M, Konstan J, Hilliard et al.: Aerosolized prolastin (α_1 -protease inhibitor) in CF. Abstract from Ninth Annual North American CF Conference 1995

79. Griese M, Latzin P, Kappler M et al. α_1 -Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007;29:240-250

* Important and recent article looking at patient response to inhaled α_1 -antitrypsin

80. Vogelmeier C, Hubbard RC, Fells GA et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991;87:482-488

*Important article establishing potential for SLPI in inhibition of NE

81. Morrison HM, Kramps JA, Dijkman JH, Stockley RA. Comparison of concentrations of two proteinase inhibitors, porcine pancreatic elastase inhibitory capacity, and cell profiles in sequential bronchoalveolar lavage samples. *Thorax* 1986;41:435-441
82. Kramps JA, Franken C, Dijkman JH. Quality of anti-leucoprotease relative to alpha 1-proteinase inhibitor in peripheral airspaces of the human lung. *Clin Sci* 1988;75:351-353
83. Boudier C, Pelletier A, Gast A et al. The elastase inhibitory capacity and the alpha 1-proteinase inhibitor and bronchial inhibitor content of bronchoalveolar lavage fluids from healthy subjects. *Biol Chem Hoppe Seyler* 1987;368:981-990
84. Hochstrasser K, Reichert R, Schwarz S, Werle E. [Isolation and characterisation of a protease inhibitor from human bronchial secretion.] Isolierung und Charakterisierung eines Proteaseninhibitors aus menschlichen Bronchialsekret. *Hoppe Seylers Z Physiol Chem* 1972;353:221-226
85. Travis J. Structure, function, and control of neutrophil proteinases. *Am J Med* 1988;84:37-42

86. Rice WG, Weiss SJ. Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. *Science* 1990;249:178-181
87. Bruch M, Bieth JG. Influence of elastin on the inhibition of leucocyte elastase by alpha 1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor. *Biochem J* 1986;238:269-273
88. Gillissen A, Birrer P, McElvaney NG et al. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. *J Appl Physiol* 1993;75:825-832
89. Vogelmeier C, Buhl R, Hoyt RF et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. *J Appl Physiol* 1990;69:1843-1848
- * Important article establishing potential for SLPI in inhibition of NE
90. Guyot N, Zani ML, Maurel MC et al. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. *Biochemistry* 2005;44:15610-8
- * Article of interest presenting elafin as a future target.

91. Butler MW, Robertson I, Greene CM et al. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. *J Biol Chem* 2006;281:34730-5
- * Recent article looking at the anti-inflammatory effects of elafin
92. Woods DE, Cantin A, Cooley J et al. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic *Pseudomonas aeruginosa* lung infection. *Pediatr Pulmonol* 2005; 39(2):141-9
93. Cantin AM, Woods DE. Aerosolized prolactin suppresses bacterial proliferation in a model of chronic *Pseudomonas aeruginosa* lung infection. *Am J Respir Crit Care Med*. 1999 Oct;160(4):1130-5
94. Snider GL, Stone PJ, Lucey EC et al. Eglin-c, a polypeptide derived from the medicinal leech, prevents human neutrophil elastase-induced emphysema and bronchial secretory cell metaplasia in the hamster. *Am Rev Respir Dis* 1985;132:1155-1161
95. Lucey EC, Stone PJ, Christensen TG et al. Effect of varying the time interval between intratracheal administration of eglin-c and human neutrophil elastase on prevention of emphysema and secretory cell metaplasia in hamsters. With observations on the fate of eglin-c and the effect of repeated instillations. *Am Rev Respir Dis* 1986;134:471-475

96. Nick HP, Probst A, Schnebli HP. Development of eglin-c as a drug pharmacokinetics. In: Horl H, Heidiand A, eds. *Proteases II*. New York: Plenum Press, 1988;83-88
97. McWherter CA, Walkenhorst WF, Campbell EJ, Glover GI. Novel inhibitors of human leukocyte elastase and cathepsin G. Sequence variants of squash seed protease inhibitors with altered protease specificity. *Biochemistry* 1989;28:5708-5714
98. Powers JC, Harper HW. Inhibitors of serine proteases. In: Barrett AJ, Salvesen G, eds. *Proteinase Inhibitors*. New York: Elsevier, 1986;55-152
99. Lee RL, Rancourt RC, Del Val G et al. Thioredoxin and dihydrolipoic acid inhibit elastase activity in cystic fibrosis sputum. *Am J Physiol Lung Cell Mol Physiol* 2005;289(5): L875-82
100. Brillard-Bourdet M, Hamdaoui A, Hajjar E et al. A novel locust (*Schistocerca gregaria*) serine protease inhibitor with a high affinity for neutrophil elastase. *Biochem J* 2006;400(3):467-76
101. Powers JC, Gupton BF, Harley AD et al. Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G.

Inhibition with peptide chloromethyl ketones. *Biochim Biophys Acta*
1977;485:156-166

102. Kettner C, Shenvi A, Watanabe S et al.: A peptide boronic acid inhibitor of elastase. In: Taylor JC, Mittman C, eds. *Pulmonary Emphysema and Proteolysis*. New York: Academic Press, 1987;65-72
103. Kennedy AJ, Cline A, Ney UM et al. The effect of a peptide aldehyde reversible inhibitor of elastase on a human leucocyte elastase-induced model of emphysema in the hamster. *Eur J Respir Dis* 1987;71:472-478
104. Williams JC, Falcone RC, Knee C et al. Biologic characterization of ICI 200, 880 and ICI 200, 355, novel inhibitors of human neutrophil elastase. *Am Rev Respir Dis* 1991;144:875-883
105. Doherty JB, Ashe BM, Argenbright LW et al. Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase. *Nature* 1986;322:192-194
106. Gorrini M, Lupi A, Viglio S et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. *Am J Respir Cell Mol Biol* 2001;25(4):492-9

107. Rees DD, Brain JD, Wohl ME et al. Inhibition of neutrophil elastase in CF sputum by L-658, 758. *J Pharmacol Exp Ther* 1997;283(3):1201-1206
108. Campbell EJ, Senior RM, McDonald JA, Cox DL. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. *J Clin Invest* 1982;70:845-852
109. Delacourt C, Herigault S, Delclaux C et al. Protection against acute lung injury by intravenous or intratracheal pre-treatment with EPI-hNE-4, a new potent neutrophil elastase inhibitor. *Am J Respir Cell Mol Biol* 2002 26(3):266-268
110. Grimbert D, Vecellio L, Delepine P et al. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. *J Aerosol Med* 2003;16(2):121-129
111. Attucci S, Gauthier A, Korkmaz B et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. *J Pharmacol Exp Ther* 2006;318(2):803-809
112. Flotte TR, Zeitlin PL, Reynolds TC et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-

associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. *Hum Gene Ther* 2003;14(11):1079-88

113. Canonico AE, Brigham KL, Carmichael LC et al. Plasmid-liposome transfer of the alpha 1 antitrypsin gene to cystic fibrosis bronchial epithelial cells prevents elastase-induced cell detachment and cytokine release. *Am J Respir Cell Mol Biol* 1996; 14(4):348-5

* Interesting article in the area of gene therapy.

114. Brantly ML, Spencer LT, Humphries M et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha1-antitrypsin (AAT) vector in AAT-deficient adults. *Hum Gene Ther*. 2006;17:1177-86.

115. Kuhn RJ. Formulation of aerosolized therapeutics. *Chest* 2001;120:94-98

* Interesting review on the difficulties of drug delivery in the matrix of the sputum

116. Levy J, Smith AL, Kenny MA et al. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. *J Infect Dis* 1983;148:1069-76

117. Cystic Fibrosis Foundation. Consensus conference: use of aerosolized antibiotics in CF patients (vol VIII). Bethesda, MD: Cystic Fibrosis Foundation, 1997; section I

118. Touw DJ, Brimicombe RW, Hodson ME et al. Inhalation of antibiotics in cystic fibrosis. *Eur Respir J* 1995;8:1594-1604

119. Matthews LW, Doershuk CF. Inhalation therapy and postural drainage for the treatment of cystic fibrosis. *Mod Probl Paediatr* 1967;10:297-314

120. Spencer LT, Humphries JE, Brantly ML; Transgenic Human Alpha 1-antitrypsin Study Group. Antibody response to aerosolized transgenic human alpha 1-antitrypsin. *N Engl J Med* 2005;352:2030-1

